Analyst Price Target is $4.20
▲ +238.71% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for CASI Pharmaceuticals in the last 3 months. The average price target is $4.20, with a high forecast of $5.00 and a low forecast of $3.80. The average price target represents a 238.71% upside from the last price of $1.24.
Current Consensus is
The current consensus among 4 contributing investment analysts is to buy stock in CASI Pharmaceuticals. This Buy consensus rating has held steady for over two years.
CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong, and Macau. Its products include Zevalin, Evomela, and Marqibo. The company was founded in 1991 and is headquartered in Rockville, MD.